- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04647240
Dermacyte® Amniotic Wound Care Liquid for the Treatment of Non-Healing Venous Stasis Ulcers
A Two Part, Randomized Study of Dermacyte® Amniotic Wound Care Liquid for the Treatment of Non-Healing Venous Stasis Ulcers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
DL-VSU-201 is a multi-center, two-part study in patients with VSU (n=40). The run-in phase of the study (Part 1) will enroll 10 eligible subjects. In part 1, patients will be randomized 1:1 to receive active Dermacyte once weekly or once every two weeks with standard of care. The data from Part 1 will be reviewed to determine the administration frequency of the study product (once weekly or once every two weeks) in Part 2 of the Study.
In Part 2, approximately 30 subjects will be randomized 1:1 to receive Dermacyte Liquid or placebo (0.9% NaCl) with standard of care. Subjects will be followed for 12 weeks.
Subjects will receive localized subcutaneous injection of Dermacyte® Liquid or placebo into and/or around the wound bed during during clinic visits over a 12-week period and assessed for safety and efficacy measures at Screening, Baseline, and Weeks 4, 8, and 12. Percent reduction of the wound surface area will be formally collected at Baseline, Weeks 4, 8, and 12. To assess healing, the ulcer will be evaluated by assessing the change in the surface area (L X W) from Baseline. Overall change in VAS from Baseline to Week 12 will be evaluated and total wound closure will be evaluated at Week 12.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Chris Broderick
- Phone Number: 919-921-8105
- Email: info@merakris.com
Study Locations
-
-
Virginia
-
Salem, Virginia, United States, 24153
- Recruiting
- Salem VAMC
-
Contact:
- YVETTE SPANGLER
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-75 years of age at the time of signing informed consent
Must have full thickness ulcer
- Ulcer surface area > 1 cm2 and < 25 cm2
- Ulcer surface area has not increased or decreased by 25% or more within 14 days of Baseline
- Ulcer depth > 0.2 cm at the deepest point of the wound, as measured by gently inserting a pre-moistened cotton tipped applicator into the deepest part of the wound.
- Received > 28 days of standard of care prior to the Baseline visit.
- Must have adequate circulation to the affected extremity as demonstrated by ankle-brachial index (ABI) greater than or equal to 0.8 and less than or equal to 1.2 or triphasic or biphasic Doppler arterial waveforms at the ankle of affected leg; if subject has undergone lower extremity stenting or bypass where ABI would be considered unreliable to assess microvascular circulation, subjects must have transcutaneous (TcPO2) > 40 mmHg
- VSU caused by underlying venous reflux disease with physiological reflux lasting greater than 500 milliseconds for superficial veins and 1.0 seconds for deep veins, as confirmed by most recent Doppler ultrasound venous mapping from Baseline; historical results within the last three years allowed
- Must have previously undergone venous hemodynamic correction via compression, surgical venous stripping, sclerotherapy, endovenous laser ablation and/or endovenous radiofrequency ablation
- Must be able to speak English
Exclusion Criteria:
- Subject must not be currently receiving topical antimicrobials and ulcer must not be infected, as determined by clinical assessment (e.g. odor, color, visual appearance) rather than culture
- Ulcer must not have exposed bone, tendon, or ligament
- Subject must not have another ulcer within 3 cm from the ulcer receiving investigational treatment
- Must not have underlying osteomyelitis
- Must not be actively receiving any skin graft substitutes or regenerative therapies within 30 days prior to Baseline
- Must not have chronic musculoskeletal disorders or other diseases that limit ambulation
- Must not be receiving oral, systemically administered corticosteroids; excluded if receiving local corticosteroid injections in the lower extremities
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Dermacyte® Liquid (human amniotic fluid)
Dermacyte® Liquid (human amniotic fluid) solution 1.0mL to 2.0mL weekly
|
Subcutaneous injection into and/or around wound bed weekly
|
Placebo Comparator: Placebo (0.9% saline)
Matching placebo solution 1.0mL to 2.0mL weekly
|
Subcutaneous injection into and/or around wound bed weekly
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability
Time Frame: Baseline to Week 12
|
Evaluated via patient and/or Investigator reported adverse events that occur during the study
|
Baseline to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total wound closure
Time Frame: Baseline to Week 12
|
Total ulcer closure demonstrated by skin re-epithelization without drainage or dressing requirements at two consecutive visits > 2 weeks
|
Baseline to Week 12
|
Ulcer size
Time Frame: Baseline to Week 12
|
Percent reduction of the ulcer surface area
|
Baseline to Week 12
|
Change in pain
Time Frame: Baseline to Weeks 4, 8 and 12
|
Change in patient-reported index ulcer-related pain via the score from the Visual Analogue Scale (VAS)
|
Baseline to Weeks 4, 8 and 12
|
Change in health-related quality of life
Time Frame: Baseline to Week 12
|
SF-36, DLQI, and Wound-QOL
|
Baseline to Week 12
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DL-VSU-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Leg Ulcer
-
Gloucestershire Hospitals NHS Foundation TrustNot yet recruitingLeg Ulcer | Venous Leg Ulcer | Venous Insufficiency of Leg | Venous Ulcer
-
Tactile MedicalCompletedVenous Insufficiency | Venous Leg Ulcer | Chronic Venous Insufficiency | Venous Ulcer | Venous Stasis UlcerUnited States
-
DeRoyal Industries, Inc.Royal College of Surgeons, Ireland; Enterprise Ireland; Tyndall National InstituteCompletedVenous Leg Ulcer | Venous Insufficiency of LegIreland
-
Chang Gung Memorial HospitalRecruitingVenous Leg Ulcer | Venous Insufficiency of Leg | Venous Occlusion | Contrast Media ReactionTaiwan
-
Ortec InternationalCompletedVenous Leg Ulcer | Venous Stasis UlcerUnited States
-
Firstkind LtdTerminatedLeg Ulcer | Venous Leg Ulcer | Venous UlcerCanada
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States, Australia, Germany, Italy, United Kingdom, New Zealand, Ireland
-
Firstkind LtdCompletedLeg Ulcer | Venous Leg Ulcer | Wound | Wound Leg | Leg Ulcers VenousUnited Kingdom
-
Mansoura UniversityActive, not recruitingVaricose Veins | Venous Insufficiency | Venous Leg Ulcer | Venous RefluxEgypt
Clinical Trials on Dermacyte® Liquid (human amniotic fluid)
-
University of UtahCompletedSARS CoV-2United States
-
University of UtahCompletedSARS CoV-2 InfectionUnited States
-
University of UtahRecruiting
-
Organicell Regenerative MedicineCompleted
-
Applied Biologics, LLCFondren Orthopedic Group L.L.P.; Texas Orthopedic HospitalUnknownRotator Cuff Tear | Fatty AtrophyUnited States
-
University of UtahCompletedWounds and InjuriesUnited States
-
MiMedx Group, Inc.CompletedPudendal NerveUnited States
-
Amniox Medical, Inc.TerminatedFoot Ulcer, DiabeticUnited States
-
Baxalta now part of ShireTakeda Development Center Americas, Inc.CompletedChronic Inflammatory Demyelinating PolyradiculoneuropathyUnited States, Israel, Canada, Spain, Czechia, Croatia, Poland, Italy, Serbia, Germany, Argentina, Mexico, Turkey, United Kingdom, Brazil, France, Greece, Slovakia, Colombia, Denmark, Norway, Sweden
-
Mazen Dimachkie, MDCSL BehringCompletedMyasthenia GravisUnited States, Canada